Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$2.44
+1.7%
$2.86
$2.35
$4.60
$21.60M1.1435,225 shs3,566 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$13.00
-0.6%
$13.25
$1.27
$15.85
$20.88M1.212,153 shs1,766 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$0.61
0.0%
$0.59
$0.24
$4.47
$20.25M0.59969,952 shs31,734 shs
ULURU Inc. stock logo
ULUR
ULURU
$0.00
$0.10
$0.79
$5.35M-3.136,691 shsN/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
0.00%+1.27%-25.00%-18.64%-22.33%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00%-1.52%-4.18%+0.54%+870.15%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-0.02%-0.97%-26.93%+135.74%-80.87%
ULURU Inc. stock logo
ULUR
ULURU
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
1.5792 of 5 stars
3.35.00.00.00.00.00.0
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1.0625 of 5 stars
0.03.00.00.02.91.70.6
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
4.5932 of 5 stars
3.15.00.04.40.04.21.3
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
2.50
Moderate Buy$12.00391.80% Upside
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2.25
Hold$5.00719.67% Upside
ULURU Inc. stock logo
ULUR
ULURU
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$25.91K833.46N/AN/A($0.69) per share-3.54
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/A$14.25 per shareN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$1.18 per shareN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$4.05M-$0.17N/AN/AN/AN/AN/A-8.14%8/11/2025 (Estimated)
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/6/2025 (Estimated)
ULURU Inc. stock logo
ULUR
ULURU
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest ULUR, DARE, FNCH, and RLMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.25N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million
5/12/2025Q1 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.31-$0.58-$0.27-$0.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/A
0.56
0.56
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
5.29
5.29
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
6.70%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
21.77%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
45.24%
ULURU Inc. stock logo
ULUR
ULURU
N/A

Insider Ownership

CompanyInsider Ownership
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
4.00%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
44.90%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
20.70%
ULURU Inc. stock logo
ULUR
ULURU
1.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
308.85 million8.50 millionNot Optionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
1033.19 million26.32 millionOptionable
ULURU Inc. stock logo
ULUR
ULURU
230.57 million30.24 millionNot Optionable

Recent News About These Companies

GPs Honor Indigenous Leadership During NAIDOC Week
Shadows falling across the land
Uluru with friends
Uluru Australia (Mala Walk) Walking Tour
Defining Moments in Australian History: Azaria Chamberlain final inquest

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dare Bioscience stock logo

Dare Bioscience NASDAQ:DARE

$2.44 +0.04 (+1.67%)
As of 11:15 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$13.00 -0.08 (-0.57%)
As of 07/7/2025 11:45 AM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Relmada Therapeutics stock logo

Relmada Therapeutics NASDAQ:RLMD

$0.61 0.00 (-0.02%)
As of 11:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

ULURU stock logo

ULURU OTCMKTS:ULUR

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.